[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100299898":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":50,"centralContacts":55,"locations":60,"responsibleParty":95,"collaborators":23,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":23,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":23,"enrollmentInfo":106,"targetDuration":23,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":23,"overallStatus":84,"whyStopped":23,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Supportive care (SRS\u002FSBRT, neurocognitive testing)","EXPERIMENTAL","Patients undergo SRS on day 1 or SBRT for 3 fractions over days 1-7 and undergo neurocognitive testing at baseline, 4, and 12 months after undergoing SRS or SBRT.",[13,14,15,16],"Procedure: Cognitive Assessment","Radiation: Stereotactic Radiosurgery","Radiation: Stereotactic Body Radiation Therapy","Other: Quality-of-Life Assessment",[18,24,36,44],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Cognitive Assessment","Undergo assessment of neurocognitive function",[9],null,{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"RADIATION","Stereotactic Radiosurgery","Undergo SRS",[9],[30,31,32,33,34,35],"Stereotactic External Beam Irradiation","stereotactic external-beam radiation therapy","stereotactic radiation therapy","Stereotactic Radiotherapy","stereotaxic radiation therapy","stereotaxic radiosurgery",{"type":25,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Stereotactic Body Radiation Therapy","Undergo SBRT",[9],[41,42,43],"SBRT","SABR","Stereotactic Ablative Body Radiation Therapy",{"type":6,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Quality-of-Life Assessment","Ancillary studies",[9],[49],"Quality of Life Assessment",[51],{"name":52,"affiliation":53,"role":54},"Wenyin Shi, MD","Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","PRINCIPAL_INVESTIGATOR",[56],{"name":52,"role":57,"phone":58,"phoneExt":23,"email":59},"CONTACT","(215) 955-6702","wenyin.shi@jefferson.edu",[61,82],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Jefferson Health New Jersey","NOT_YET_RECRUITING","Sewell","New Jersey","08080","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-75.14434,39.7665,{"lat":73,"lon":72},[76,80],{"name":77,"role":57,"phone":78,"phoneExt":23,"email":79},"Karishma Kurowski, MPH","856-341-5199","karishma.kurowski@jefferson.edu",{"name":81,"role":54,"phone":23,"phoneExt":23,"email":23},"Tamara LaCouture, MD",{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":67,"countryCode":68,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Sidney Kimmel Cancer Center at Thomas Jefferson University","RECRUITING","Philadelphia","Pennsylvania","19107",{"type":70,"coordinates":89},[90,91],-75.16362,39.95238,{"lat":91,"lon":90},[94],{"name":52,"role":57,"phone":58,"phoneExt":23,"email":23},{"type":96,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100299898","neurocognition-in-patients-with-multiple-brain-metastases-treated-with-radiosurgery-100299898",false,"NCT03184038","Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery","Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study","Inclusion Criteria:\n\n* Pathologically proven solid tumor malignancy (except for small cell lung cancer \\[SCLC\\], germ cell tumor)\n* Karnofsky performance status \\>= 60\n* 1 to 10 brain metastases (mets) (no more than two lesions and\u002For cavities \\>= 3 cm in maximum diameter)\n* Maximum diameter of brain metastasis or resection cavity is 6 cm\n* Serum creatinine =\\\u003C 3 mg\u002FdL and creatinine clearance \\>= 30 ml\u002Fmin\n* Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol\n* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose\n* Patient able to provide his\u002Fher own written informed consent and speak English\n\nExclusion Criteria:\n\n* Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor\n* Prior brain surgery =\\\u003C 14 days prior to enrollment\n* Planned chemotherapy during radiosurgery\n* Leptomeningeal metastases\n* Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months\n* Pregnant women","ALL","18 Years",{"count":107,"type":108},90,"ESTIMATED","INTERVENTIONAL",[111],"NA","This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.",[114,115],"Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm","2026-05-20",{"date":118,"type":119},"2026-05-22","ACTUAL",{"date":121,"type":119},"2017-02-21",{"date":123,"type":108},"2026-09-30",{"name":53,"class":6},2]